Specifically, CAMK2B, one of the top 5% of genes associated with BCR-ABL1 in our prediction, is a target of cyclosporin A, which can sensitize BCR-ABL-positive leukemia to BCR-ABL inhibitors [32]. The gene discussed is ABL1; the disease is leukemia.